Biodistribution of 225Ra citrate in mice

Retention of daughter radioisotopes in bone

Stephen Kennel, Trish Lankford, Marc Garland, John P. Sundberg, Saed Mirzadeh

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Alpha-particle-emitting radionuclides have potential for therapy of localized disease due to their high linear energy transformation and short pathlengths. Radiometals that home naturally to bone can be exploited for this purpose, and 223Ra (t1/2=11.4 days) recently has been studied for therapy of bone tumors in mice and rats. Actinium-225 (t 1/2=10 days) is also an attractive radioisotope for endoradiotherapy. In a single decay of a 225Ac nucleus and its subsequent decay daughters, over 27 MeV (∼90% of total energy) is released by sequential emission of four α particles, ranging in energy from 5.7 to 8.4 MeV. Although Ac3+ does not home naturally to bone, its parent radioisotope 225Ra (β-, t1/2=15 days) can be used as an in vivo source for 225Ac. Thus, injection of 225Ra takes advantage of the bone-homing properties of radium coupled with the significant amount of energy released from the 225Ac decay chain. Our data confirm that a large fraction of radium citrate injected intravenously into mice localizes rapidly in bone. Injected doses per gram (ID/g) for 225Ra range from 25% in skull to about 10% in sternum. Once deposited, the 225Ra remains in the bone with a biological half life of >40 days. Furthermore, >95% of the daughter radioisotope, 225Ac, is retained in the bone. However, a significant fraction of one of the daughter radioisotopes, 213Bi, is found in kidney. The biodistribution data indicate that 225Ra injection should be a powerful agent for killing cells associated with bone; however, the toxicity of this radioisotope which is similar to that of other α emitters limits the dose that can be tolerated.

Original languageEnglish (US)
Pages (from-to)859-867
Number of pages9
JournalNuclear Medicine and Biology
Volume32
Issue number8
DOIs
StatePublished - Nov 1 2005
Externally publishedYes

Fingerprint

Citric Acid
Radioisotopes
Bone and Bones
Radium
Actinium
Alpha Particles
Sternum
Injections
Skull
Half-Life
Kidney
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Biodistribution of 225Ra citrate in mice : Retention of daughter radioisotopes in bone. / Kennel, Stephen; Lankford, Trish; Garland, Marc; Sundberg, John P.; Mirzadeh, Saed.

In: Nuclear Medicine and Biology, Vol. 32, No. 8, 01.11.2005, p. 859-867.

Research output: Contribution to journalArticle

Kennel, Stephen ; Lankford, Trish ; Garland, Marc ; Sundberg, John P. ; Mirzadeh, Saed. / Biodistribution of 225Ra citrate in mice : Retention of daughter radioisotopes in bone. In: Nuclear Medicine and Biology. 2005 ; Vol. 32, No. 8. pp. 859-867.
@article{c9bdd50d5c114b53b9b39630c074529a,
title = "Biodistribution of 225Ra citrate in mice: Retention of daughter radioisotopes in bone",
abstract = "Alpha-particle-emitting radionuclides have potential for therapy of localized disease due to their high linear energy transformation and short pathlengths. Radiometals that home naturally to bone can be exploited for this purpose, and 223Ra (t1/2=11.4 days) recently has been studied for therapy of bone tumors in mice and rats. Actinium-225 (t 1/2=10 days) is also an attractive radioisotope for endoradiotherapy. In a single decay of a 225Ac nucleus and its subsequent decay daughters, over 27 MeV (∼90{\%} of total energy) is released by sequential emission of four α particles, ranging in energy from 5.7 to 8.4 MeV. Although Ac3+ does not home naturally to bone, its parent radioisotope 225Ra (β-, t1/2=15 days) can be used as an in vivo source for 225Ac. Thus, injection of 225Ra takes advantage of the bone-homing properties of radium coupled with the significant amount of energy released from the 225Ac decay chain. Our data confirm that a large fraction of radium citrate injected intravenously into mice localizes rapidly in bone. Injected doses per gram (ID/g) for 225Ra range from 25{\%} in skull to about 10{\%} in sternum. Once deposited, the 225Ra remains in the bone with a biological half life of >40 days. Furthermore, >95{\%} of the daughter radioisotope, 225Ac, is retained in the bone. However, a significant fraction of one of the daughter radioisotopes, 213Bi, is found in kidney. The biodistribution data indicate that 225Ra injection should be a powerful agent for killing cells associated with bone; however, the toxicity of this radioisotope which is similar to that of other α emitters limits the dose that can be tolerated.",
author = "Stephen Kennel and Trish Lankford and Marc Garland and Sundberg, {John P.} and Saed Mirzadeh",
year = "2005",
month = "11",
day = "1",
doi = "10.1016/j.nucmedbio.2005.05.009",
language = "English (US)",
volume = "32",
pages = "859--867",
journal = "Nuclear Medicine and Biology",
issn = "0969-8051",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Biodistribution of 225Ra citrate in mice

T2 - Retention of daughter radioisotopes in bone

AU - Kennel, Stephen

AU - Lankford, Trish

AU - Garland, Marc

AU - Sundberg, John P.

AU - Mirzadeh, Saed

PY - 2005/11/1

Y1 - 2005/11/1

N2 - Alpha-particle-emitting radionuclides have potential for therapy of localized disease due to their high linear energy transformation and short pathlengths. Radiometals that home naturally to bone can be exploited for this purpose, and 223Ra (t1/2=11.4 days) recently has been studied for therapy of bone tumors in mice and rats. Actinium-225 (t 1/2=10 days) is also an attractive radioisotope for endoradiotherapy. In a single decay of a 225Ac nucleus and its subsequent decay daughters, over 27 MeV (∼90% of total energy) is released by sequential emission of four α particles, ranging in energy from 5.7 to 8.4 MeV. Although Ac3+ does not home naturally to bone, its parent radioisotope 225Ra (β-, t1/2=15 days) can be used as an in vivo source for 225Ac. Thus, injection of 225Ra takes advantage of the bone-homing properties of radium coupled with the significant amount of energy released from the 225Ac decay chain. Our data confirm that a large fraction of radium citrate injected intravenously into mice localizes rapidly in bone. Injected doses per gram (ID/g) for 225Ra range from 25% in skull to about 10% in sternum. Once deposited, the 225Ra remains in the bone with a biological half life of >40 days. Furthermore, >95% of the daughter radioisotope, 225Ac, is retained in the bone. However, a significant fraction of one of the daughter radioisotopes, 213Bi, is found in kidney. The biodistribution data indicate that 225Ra injection should be a powerful agent for killing cells associated with bone; however, the toxicity of this radioisotope which is similar to that of other α emitters limits the dose that can be tolerated.

AB - Alpha-particle-emitting radionuclides have potential for therapy of localized disease due to their high linear energy transformation and short pathlengths. Radiometals that home naturally to bone can be exploited for this purpose, and 223Ra (t1/2=11.4 days) recently has been studied for therapy of bone tumors in mice and rats. Actinium-225 (t 1/2=10 days) is also an attractive radioisotope for endoradiotherapy. In a single decay of a 225Ac nucleus and its subsequent decay daughters, over 27 MeV (∼90% of total energy) is released by sequential emission of four α particles, ranging in energy from 5.7 to 8.4 MeV. Although Ac3+ does not home naturally to bone, its parent radioisotope 225Ra (β-, t1/2=15 days) can be used as an in vivo source for 225Ac. Thus, injection of 225Ra takes advantage of the bone-homing properties of radium coupled with the significant amount of energy released from the 225Ac decay chain. Our data confirm that a large fraction of radium citrate injected intravenously into mice localizes rapidly in bone. Injected doses per gram (ID/g) for 225Ra range from 25% in skull to about 10% in sternum. Once deposited, the 225Ra remains in the bone with a biological half life of >40 days. Furthermore, >95% of the daughter radioisotope, 225Ac, is retained in the bone. However, a significant fraction of one of the daughter radioisotopes, 213Bi, is found in kidney. The biodistribution data indicate that 225Ra injection should be a powerful agent for killing cells associated with bone; however, the toxicity of this radioisotope which is similar to that of other α emitters limits the dose that can be tolerated.

UR - http://www.scopus.com/inward/record.url?scp=27144489049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144489049&partnerID=8YFLogxK

U2 - 10.1016/j.nucmedbio.2005.05.009

DO - 10.1016/j.nucmedbio.2005.05.009

M3 - Article

VL - 32

SP - 859

EP - 867

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

IS - 8

ER -